« Optimal » vs actual hematocrit in obesity and overweight

Jean-Frédéric Brun1, Emmanuelle Varlet-Marie2,3, Christine Fédou1

  • 1UMR CNRS 9214-Inserm U1046 « Physiopathologie & Médecine Expérimentale du Coeur et des Muscles - PHYMEDEXP », Unité d'Explorations Métaboliques (CERAMM), Université de Montpellier, Département de Physiologie Clinique,Hôpital Lapeyronie CHU Montpellier, France.

Equations of blood viscosity provide a prediction of the 'optimal' hematocrit' (hct) as the hct resulting in the highest value of the bell-shaped curve of hematocrit/viscosity ratio h/η. We investigated if overweight and obesity have an influence on these parameters. We compared 32 normal weight subjects, 40 overweight (BMI 25-30) and 38 obese subjects. There was no difference in the theoretical curve of h/η. The actual h/η is the same in the 3 groups but is always higher than the theoretical h/η in all groups. The actual h/η is lower in overweight than controls (p = 0.011). Modeling yields the same value of theoretical optimal hct across BMI classes. The 3 groups have the same values of actual hct, but actual is significantly lower than optimal in all cases (p < 0.001). Hematocrit is lower than predicted due to a discrepancy between predicted and actual h/η which is due to the inter-subject variability of RBC rigidity ...   The discrepancy between optimal and actual h/η is negatively correlated to RBC rigidity indexes even if the model uses a fixed value of these indexes. Thus keeping in mind that the optimal hct should not be the same in the various parts of the vascular bed, its theoretical prediction with Quemada's equation appears to predict a value higher than actual hematocrit but well correlated to it, and the agreement between optimal and actual hct is dependent on RBC flexibility. This leads to think that the body sets hematocrit below its ideal value in sedentary subjects in order to cope with the need of increasing blood viscosity factors in case of exercise without impairing O2 supply to tissues.

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
325
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
343
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
262
Hypodermis01:02

Hypodermis

The hypodermis (the subcutaneous layer or superficial fascia) is present directly below the dermis. It connects the skin to the underlying fascia (fibrous tissue) of the bones and muscles. It is not strictly a part of the skin, although the border between the hypodermis and dermis can be difficult to distinguish. The hypodermis consists of well-vascularized, loose, areolar connective tissue and adipose tissue, which functions as a mode of fat storage and provides insulation and cushioning for...
8.3K
Body Water Content and Fluid Compartments01:19

Body Water Content and Fluid Compartments

Life's biochemical processes occur within aqueous solutions. Solutes are substances that are dissolved within these solutions. The human body contains a variety of solutes, which can differ across various body parts. These can encompass proteins—such as those responsible for clotting and carbohydrate transport—as well as electrolytes. In medicine, an electrolyte is often described as a mineral ion derived from a salt possessing an electric charge. Examples include sodium ions...
4.9K